Side by side
Retatrutide vs SLU-PP-332
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Retatrutide | SLU-PP-332 | |
|---|---|---|
| What it is | An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere. | A mouse compound that got a press release. It reproduced some effects of endurance training in mice, and no human has ever taken it. |
| EvidenceHow much human evidence exists, not how well it works. | Early human trials | Preclinical |
| Regulatory statusReviewed 2026-08-12 | Investigational. Not approved for human use in any jurisdiction. Sold only as a research chemical, with no manufacturing standard behind that label. | Not approved anywhere and not in human trials. An academic research compound sold as a research chemical, typically as a powder with no pharmaceutical manufacturing behind it. |
| Routes | Subcutaneous | Oral, Subcutaneous |
| Half-life | 144 hours | Not recorded |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $1.25/mg | $1.00/mg |
| Median per mg | $5.17/mg | $13.41/mg |
| Vendors with a price | 37 | 12 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze. | A small molecule, not a peptide. Solvent choice varies, and vendors rarely say what theirs is. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.